Western Australian Institute for Medical Research (WAIMR)


http://www.waimr.uwa.edu.au

Professor Peter Klinken

Peter Klinken

Professor Peter Klinken is the Director of the Western Australian Institute for Medical Research (WAIMR) which is the State's premier adult medical research institute.

Professor Klinken obtained his PhD in Biochemistry from The University of Western Australia in 1982 and was a Fogarty International Fellow at the US National Institutes of Health in Washington, between 1984 and 1986.

From there he returned to work at the Walter and Eliza Hall Institute in Melbourne as an NHMRC Postdoctoral Fellow between 1987 and 1988

In 1989 he became a Lecturer in Biochemistry at the University of Western Australia, before being appointed Professor in Clinical Biochemistry in 1994.

Between 2000 and 2002 he was the Director of Research at Royal Perth Hospital.

His research interests encompass the regulation of red blood cell formation and ability of leukemic cells to develop different features and functions. He also has a long-standing interest in identifying genes which can cause cancer or leukemia. This work is supported primarily by the NHMRC.

Qualifications

BSc (Hons), PhD, DipEd

Research Interests

  • Haemopoiesis
  • Erythropoiesis
  • Erythropoiesis signalling

Top 10 Publications

  1. Klinken SP, Alexander WS, Adams JM. 1988. Hemopoietic lineage switch: v-raf oncogene converts Eµ-myc transgenic B cells into macrophages. Cell 53(6):857-67. [NCBI PubMed Entry]
  2. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. 1991. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eµ-myc transgenic mice. Cell 65(5):753-63. [NCBI PubMed Entry]
  3. Klinken SP, Nicola NA, Johnson GR. 1988. In vitro-derived leukemic erythroid cell lines induced by a raf- and myc-containing retrovirus differentiate in response to erythropoietin. Proceedings of the National Academy of Sciences of the USA 85(22):8506-10. [NCBI PubMed Entry]
  4. Williams JH, Daly LN, Ingley E, Beaumont JG, Tilbrook PA, Lalonde JP, Stillitano JP, Klinken SP. 1999. HLS7, a hemopoietic lineage switch gene homologous to the leukemia-inducing gene MLF1. The EMBO Journal 18(20):5559-66. [NCBI PubMed Entry]
  5. Tilbrook PA, Ingley E, Williams JH, Hibbs ML, Klinken SP. 1997. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. The EMBO Journal 16(7):1610-9. [NCBI PubMed Entry]
  6. Busfield SJ, Klinken SP. 1992. Erythropoietin-induced stimulation of differentiation and proliferation in J2E cells is not mimicked by chemical induction. Blood 80(2):412-9. [NCBI PubMed Entry]
  7. Principato M, Cleveland JL, Rapp UR, Holmes KL, Pierce JH, Morse HC 3rd, Klinken SP. 1990. Transformation of murine bone marrow cells with combined v-raf-v-myc oncogenes yields clonally related mature B cells and macrophages. Molecular and Cellular Biology 10(7):3562-8. [NCBI PubMed Entry]
  8. Tilbrook PA, Palmer GA, Bittorf T, McCarthy DJ, Wright MJ, Sarna MK, Linnekin D, Cull VS, Williams JH, Ingley E, Schneider-Mergener J, Krystal G, Klinken SP. 2001. Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. Cancer Research 61(6):2453-8. [NCBI PubMed Entry]
  9. Klinken SP, Fredrickson TN, Hartley JW, Yetter RA, Morse HC 3rd. 1988. Evolution of B cell lineage lymphomas in mice with a retrovirus-induced immunodeficiency syndrome, MAIDS. Journal of Immunology 140(4):1123-31. [NCBI PubMed Entry]
  10. Lalonde JP, Lim R, Ingley E, Tilbrook PA, Thompson MJ, McCulloch R, Beaumont JG, Wicking C, Eyre HJ, Sutherland GR, Howe K, Solomon E, Williams JH, Klinken SP. 2004. HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor. The Journal of Biological Chemistry 279(9):8181-9. [NCBI PubMed Entry]